View Item 

Show simple item record

Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids

dc.contributor.authorNoureldin, Mohamed
dc.contributor.authorHiggins, Peter D. R.
dc.contributor.authorGovani, Shail M.
dc.contributor.authorCohen‐mekelburg, Shirley
dc.contributor.authorKenney, Brooke C.
dc.contributor.authorStidham, Ryan W.
dc.contributor.authorWaljee, Jennifer F.
dc.contributor.authorWaljee, Akbar K.
dc.date.accessioned2019-01-15T20:30:51Z
dc.date.available2020-03-03T21:29:35Zen
dc.date.issued2019-01
dc.identifier.citationNoureldin, Mohamed; Higgins, Peter D. R.; Govani, Shail M.; Cohen‐mekelburg, Shirley ; Kenney, Brooke C.; Stidham, Ryan W.; Waljee, Jennifer F.; Waljee, Akbar K. (2019). "Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids." Alimentary Pharmacology & Therapeutics 49(1): 74-83.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/147149
dc.publisherWiley Periodicals, Inc.
dc.titleIncidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147149/1/apt15023_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147149/2/apt15023.pdf
dc.identifier.doi10.1111/apt.15023
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceKingston REF, Marel C, Mills KL. A systematic review of the prevalence of comorbid mental health disorders in people presenting for substance use treatment in Australia. Drug Alcohol Rev. 2017; 36: 527 â 539.
dc.identifier.citedreferenceLewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004; 126: 665 â 673.
dc.identifier.citedreferenceCrockett SD, Hansen RA, Stürmer T, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012; 18: 1048 â 1056.
dc.identifier.citedreferenceQuan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICDâ 9â CM and ICDâ 10 administrative data. Med Care. 2005; 43: 1130 â 1139.
dc.identifier.citedreferenceNielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016; 25: 733 â 737.
dc.identifier.citedreferenceMoolgavkar SH, Chang ET, Watson HN, Lau EC. An assessment of the cox proportional hazards regression model for epidemiologic studies. Risk Anal. 2017; 38: 777 â 794.
dc.identifier.citedreferenceAlam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Longâ term analgesic use after lowâ risk surgery: a retrospective cohort study. Arch Intern Med. 2012; 172: 425 â 430.
dc.identifier.citedreferenceYang Z, Wilsey B, Bohm M, et al. Defining risk of prescription opioid overdose: pharmacy shopping and overlapping prescriptions among longâ term opioid users in medicaid. J Pain. 2015; 16: 445 â 453.
dc.identifier.citedreferenceDunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152: 85 â 92.
dc.identifier.citedreferenceWren AA, Bensen R, Sceats L, et al. Starting Young: trends in opioid therapy among US adolescents and young adults with inflammatory bowel disease in the Truven MarketScan Database Between 2007 and 2015. Inflamm Bowel Dis. 2018; 24: 2093 â 2103.
dc.identifier.citedreferenceVozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a populationâ based cohort study. Br J Clin Pharmacol. 2016; 81: 161 â 170.
dc.identifier.citedreferenceSayuk GS, Kanuri N, Gyawali CP, Gott BM, Nix BD, Rosenheck RA. Opioid medication use in patients with gastrointestinal diagnoses vs unexplained gastrointestinal symptoms in the US Veterans Health Administration. Aliment Pharmacol Ther. 2018; 47: 784 â 791.
dc.identifier.citedreferencevan den Brink G, Stapersma L, Vlug LE, et al. Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2018; 48: 358 â 369.
dc.identifier.citedreferenceHanson KA, Loftus EV Jr, Harmsen WS, Diehl NN, Zinsmeister AR, Sandborn WJ. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a caseâ control study. Inflamm Bowel Dis. 2009; 15: 772 â 777.
dc.identifier.citedreferenceMcCarthy M. Opioids should be last resort to treat chronic pain, says draft CDC guideline. BMJ. 2015; 351: h6905.
dc.identifier.citedreferenceDowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic painâ United States, 2016. JAMA. 2016; 315: 1624 â 1645.
dc.identifier.citedreferenceFrieden TR, Houry D. Reducing the risks of reliefâ the CDC opioidâ prescribing guideline. N Engl J Med. 2016; 374: 1501 â 1504.
dc.identifier.citedreferenceNarula N, Borges L, Steinhart AH, Colombel JF. Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States Ambulatory Care Setting from 2003 to 2011. Inflamm Bowel Dis. 2017; 23: 868 â 874.
dc.identifier.citedreferenceDocherty MJ, Jones RCW, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol. 2011; 7: 592 â 601.
dc.identifier.citedreferenceSrinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Ther Adv Gastroenterol. 2012; 5: 339 â 357.
dc.identifier.citedreferenceGajendran M, Watson AR, Bauer AJ, et al. 927 End to end VS side to side anastomosis and postâ operative Crohn’s disease quality of life and healthcare utilization: a prospective comparative effectiveness study. Gastroenterology. 2015; 148: S â 177.
dc.identifier.citedreferenceBurr NE, Smith C, West R, Hull MA, Subramanian V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol. 2018; 16: 534 â 541.e6.
dc.identifier.citedreferenceLan PX, Lee JW, Seol Yâ J, Cho Dâ W. Development of 3D PPF/DEF scaffolds using microâ stereolithography and surface modification. J Mater Sci Mater Med. 2008; 20: 271 â 279.
dc.identifier.citedreferenceWright EA, Katz JN, Abrams S, Solomon DH, Losina E. Trends in prescription of opioids from 2003â 2009 in persons with knee osteoarthritis. Arthritis Care Res (Hoboken). 2014; 66: 1489 â 1495.
dc.identifier.citedreferencePaulozzi LJ, Mack KA, Hockenberry JM. Variation among states in prescribing of opioid pain relievers and benzodiazepinesâ United States, 2012. J Safety Res. 2014; 51: 125 â 129.
dc.identifier.citedreferencePaulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J Clin Psychiatry. 2011; 72: 589 â 592.
dc.identifier.citedreferenceKenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000â 2010. Open Med. 2012; 6: e41 â e47.
dc.identifier.citedreferenceVon Korff M, Kolodny A, Deyo RA, Chou R. Longâ term opioid therapy reconsidered. Ann Intern Med. 2011; 155: 325 â 328.
dc.identifier.citedreferenceSolomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010; 170: 1968 â 1976.
dc.identifier.citedreferenceAparasu RR, Chatterjee S. Use of narcotic analgesics associated with increased falls and fractures in elderly patients with osteoarthritis. Evid Based Med. 2014; 19: 37 â 38.
dc.identifier.citedreferenceEdwards JT, Radfordâ Smith GL, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001; 16: 1235 â 1238.
dc.identifier.citedreferenceGrunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007; 5: 1126 â 1139; quiz 1121â 2.
dc.identifier.citedreferenceTargownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a populationâ based analysis. Am J Gastroenterol. 2014; 109: 1613.
dc.identifier.citedreferenceBrummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA. 2017; 152: e170504.
dc.identifier.citedreferenceGrasberger H, Noureldin M, Kao TD, et al. Increased risk for inflammatory bowel disease in congenital hypothyroidism supports the existence of a shared susceptibility factor. Sci Rep. 2018; 8: 10158.
dc.identifier.citedreferenceCrockett SD, Schectman R, Stürmer T, Kappelman MD. Topiramate use does not reduce flares of inflammatory bowel disease. Dig Dis Sci. 2014; 59: 1535 â 1543.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt15023_am.pdf
Size:
423.2KB
Format:
PDF
View/Open
Name:
apt15023.pdf
Size:
463.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.